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Abstract: Biological activity of naphthoxazoles, fused hetero-benzoxazoles and benzobicyclo[3.2.1]-derivatives was investigated in proliferation 
and inflammation based assays. The tested compounds were prepared by photocylization or photocycloaddition reactions. Effect of compounds 
on proliferation of several cancer cell lines was determined by measuring cell metabolic activity through time. Lipopolysaccharide (LPS) 
stimulation of peripheral blood mononuclear cells (PBMC) was used to investigate antiinflammatory properties of the compounds. Several 
naphthoxazoles and fused hetero-benzoxazoles inhibited TNFα protein expression in LPS stimulated PBMC, indicating possible 
antiinflammatory role which would be interesting to further investigate. Physico-chemical properties of tested compounds have been also 
studied using chromatographic lipophilicity measure, chrom logD and logP was calculated as the importance of physico-chemical properties of 
compounds at early stage of discovery of new drugs is well established. The similarities in structure and activity of some representative 
compounds affirm the need to further address their antiinflammatory properties. 
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ETEROCYCLIC compounds are the most widely used 
class in pharmaceutical and agrochemical industries. 
They exhibit numerous biological activities, among which are 
antibacterial, antifungal, antiviral, antiinflammatory, antide-
pressant etc.[1] For example, pyrazolone derivatives, phena-
zone, metamizole, aminophenazone, phenyl buta-zone and 
apazone are non-steroidal antiinflammatory drugs (NSAID) 
that exhibit antiinflammatory, analgesic and antipyretic acti-
vity due to inhibition of cyclooxygenase (COX) enzymes.[2] Pu-
rine analogues, pyrimidine analogues and antifolates are cy-
tostatic compounds that inhibit cell proliferation and are used 
in cancer treatment, as well as for autoimmune disorders.[3–5] 
 In general the oxazole moiety[6] and the bicy-
clo[3.2.1]-core[7] are important building blocks for the 
synthesis of many biologically active molecules. Some of 
the fused polycyclic compounds with the oxazole ring have 
shown antibacterial and antituberculosis[8] activities as well 
as anticancer activitiy[9] and some have been tested for 
antioxidant activity.[10] Compounds with the bicyclo[3.2.1]-
skeleton are potent inhibitors of dopamine and serotonin 
transporters and they have crutial role in treatment of 
central nervous system (CNS) and Alzheimer’s disorders.[11] 
 In our group, a whole library of both groups of these 
polycylic compounds was obtained by utilization of the 
photochemical synthesis.[12–16] Naphthoxazoles as a group 
of compounds have been known since Fisher synthesized 2-
methylnaphtho[1,2-d]oxazole and 2-methylnaphtho[2,1-
d]oxazoles in 1906.[17] In the following years many synthetic 
approaches were developed for the synthesis of these 
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fused hetero-benzoxazoles[19,20] (Figure 1) in one photo-
cyclization step by utilising light as a very clean reagent 
gave a new and easy path to this kind of polycyclic systems 
that are taxing to obtain via ground state organic synthesis. 
Syntheses of compounds containing bicy-clo[3.2.l]octane 
and bicyclo[3.2.l]octadiene core (Figure 1) are also 
documented in the literature.[21] Bicyclo[3.2.l]-skeleton can 
be constructed using different synthetic pathways, one of 
which is the photochemical cycloaddition approach that 
has been developed by our group in batch and flow 
photochemical reactor.[22–34] 
 Guided by all above mentioned compounds, we have 
selected 32 compounds from both types of photoproducts 
and investigated their biological activity in proliferation and 
inflammation based assays. Effect of compounds on 
proliferation of several cancer cell lines was determined by 
measuring cell metabolic activity through time. On the 
other hand, lipopolysaccharide (LPS) stimulation of 
peripheral blood mononuclear cells (PBMC) was used to 
investigate antiinflammatory properties of the compounds.  
 Physico-chemical properties of tested compounds 
have been studied using chromatographic lipophilicity 
measure, chrom logD and logP was calculated. The 
importance of physico-chemical properties of compounds 
at early stage of discovery of new drugs is now well 
established.[35–37] Lipophilicity measurements by reverse 
phase chromatography have been already proven as fast 
and efficient method for compound profiling in the early 
phase of optimization and results are expressed as 
Chromatographic logD (chrom logD).[38–40] In this paper we 
analysed also the physico-chemical properties of the tested 




Investigated naphthoxazoles, fused hetero-benzoxazoles 
and benzobicyclo[3.2.1]-derivatives were previously 
synthesized and completely characterized.[14,15,19,20,22] They 
were prepared by photocylization or [2+2]-photocyclo-
addition reactions from corresponding starting materials in 
very good yields. The required styryloxazoles were synthe-
sized in one step by Van Leusen reaction from aryl / he-
teroaryl substituted α,β-unsaturated aldehydes and tosyl-
methyl isocynide (TosMIC). In the case of synthesis of 2/3-
thienylethenyl- and 2/3/4-pyridylethenyloxazoles the nece-
ssary unsaturated aldehydes were prepared by Wittig reac-
tion from the corresponding aldehydes and formylme-
thylenetriphenylphosphorane. 
Chrom logD Determination 
Chrom logD values were determined from the following 
equation: chrom logD = 0.0857 × CHI – 2 (ref. 
Chromatographic Hydrophobic Index (CHI) values have 
been determined from gradient retention times (tR) as 
described by Valkó and Slegel.[41,42] These values 
approximately correspond to the volume percentage of 
organic component in the mobile phase when the 
compound elutes. CHI values were determined at pH 7.4. 
Chromatograms were obtained using an Agilent 1100 
Series HPLC instruments equipped with diode array 
detector (DAD) coupled with Micromass Quattro API mass 
spectrometer. Data acquisition and processing were 
performed with MassLynx software version 4.1. The 
column used for CHI determination was Luna C18 (50mm × 
3 mm i.d., 5 µm particle size, 100 Å). The aqueous part of 
the mobile phase was 50mM ammonium acetate adjusted 
with ammonia solution to pH 7.4. As an organic part of their 
mobile phase acetonitrile was used. The mobile phase flow 
rate was 1 mL min–1 for all measurements. The gradient 
retention times tR were measured under the following 
gradient condition: 0 to 3 min linear gradient from 0 to 100 
% acetonitrile; 3 to 3.5 min 100 % acetonitrile; 3.5 to 3.7 
min from 100 to 0 % acetonitrile; and 3.7 to 5 min re-
equilibration time with 100 % of aqueous part of the mobile 
phase. 
Biological Activity 
Effect of compounds on cell proliferation was determined 
in cancer cell lines THP-1, Jurkat and HL-60. The assay is 
based on ability of metabolically active cells to convert MTS 
tetrazolium compound to formazan product detectable by 
absorbance at 490 nm. The quantity of formazan product is 
proportional to the number of metabolically active cells. In 
this assay staurosporine was used as reference compound 
since it is a protein kinases inhibitor which induces 
apoptosis. Furthermore, antiinflammatory activity of 
compounds was determined in LPS stimulated PBMC assay. 
LPS is one of the components of Gram-negative bacteria 
cell wall and is recognized by Toll-like receptor 4 (TLR4). The 
activation of TLR4 signaling induces release of cytokines 
among which are interleukin-8 (IL-8) and tumor necrosis 
factor α (TNFα), therefore leading to inflammatory 















 I. ŠAGUD et al.: Antiinflammatory and Antiproliferative Activity of Photoproducts 193 
 




dexamethasone was used as reference compound because 
of it’s antiinflammatory activity. 
Cell Culture 
Human cell lines THP-1 (TIB-202) and Jurkat (TIB152) were 
purchased from ATCC, while human cell line HL-60 (CCL-
240) was purchased from ECACC. All cell lines were 
maintained in cell culture in RPMI medium (Lonza) 
supplemented with 10 % heat inactivated fetal bovine 
serum (FBS) (BioWest) in CO2 incubator (5 % CO2, 95 % 
humidity, 37 °C). 
Cell Proliferation Assay 
Effect of compounds on proliferation of THP-1, Jurkat and 
HL-60 cells was determined using CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay (Promega). 
 96-well plates were seeded with 30 000 HL-60, THP-
1 or Jurkat cells per well, followed by addition of three fold 
serial dilutions of test compounds using Mosquito 
instrument (TTP labtech). Staurosporine (Sigma) was used 
as reference compound. Final testing concentrations of test 
compounds were 30 µM to 13.72 nM, while of 
staurosporine was from 1 µM to 0.46 nM. Vehicle 
contained 0.3 % DMSO. Cells treated with compounds or 
vehicle were incubated for 24h, 48h and 72h in CO2 
incubator (5 % CO2, 95 % humidity, 37 °C) after which 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay 
substrate was added following manufacturer’s instructions. 
After 4h of incubation with the substrate, absorbance at 
490 nm was measured using EnVision 2104 instrument 
(Perkin Elmer). 
LPS Stimulation Assay 
Human peripheral blood mononuclear cells (PBMC) were 
isolated from healthy volunteer’s blood obtained from the 
Croatian Institute for Transfusion Medicine. Blood was 
diluted 1:1 with PBS and PBMCs were isolated by 
centrifugation in Lymphoprep (Axis-Shield) density 
gradient. 96-well plates were seeded with 200 000 PBMCs 
per well in RPMI 1640 (Lonza) medium supplemented with 
10 % FBS (Sigma). Cells were incubated with three fold 
serial dilutions of test compounds for 1h in CO2 incubator 
(5 % CO2, 95 % humidity, 37 °C), followed by overnight 
stimulation with 1 ng/mL of LPS from E. coli 0111:B4 
(Sigma) in CO2 incubator. Final testing concentrations of 
test compounds were 30 µM to 13.72 nM. Dexamethasone 
was used as reference compound and it was tested from 1 
µM to 0.46 nM. 0.3 % DMSO was used as vehicle. After 
overnight incubation, concentrations of TNFα and IL8 were 
determined in cell supernatants using 384-well format 
sandwich Elisa assay. Lumitrac 600 microplates (Greiner) 
were coated with 1 µg/mL of TNFα capture antibody (R&D 
Systems) or 2.5 µg/mL of IL8 capture antibody (R&D 
Systems). 1% BSA (Sigma), 5 % sucrose (Kemika) in PBS 
(Gibco) was used as blocking buffer, while cell supernatants 
were diluted either 4x for TNFα analysis or 150x for IL8 
analysis in 1 % BSA in PBS. Furthermore, 250 ng/mL of TNFα 
detection antibody (R&D Systems) or 25 ng/mL of IL8 
detection antibody (R&D Systems) were used in Elisa assay, 
while Chemiluminiscence ELISA Substrate (Roche) was used 
for developing the signals. Luminescent signals were 
measured using EnVision 2104 Multilabel Reader (Perkin 
Elmer). 
Data Analysis 
Measured absorbance at 490 nm was used to calculate 
percentage of cell proliferation for each compound in 
comparison to vehicle cells using Micorsoft Excel software 
v2013. Concentrations of TNFα and IL8 were calculated by 
extrapolation from their standard curves using Micorsoft 
Excel software v2013. Obtained concentrations were used 
to calculate percentages of inhibition of each compound by 
first subtracting average value of vehicle samples from all 
other samples. Furthermore, percentage of inhibition was 
calculated using formula: (1 − (compound / average of LPS 
triggered controls)) × 100. 
 In both assays, logarithm of tested compound con-
centration in M was plotted against calculated percentage 
of inhibition using GraphPad Prism v7.04 software. 
 
RESULTS AND DISCUSSION 
Chemistry 
Investigated naphthoxazoles 1–5 and 12–22, fused hetero-
benzoxazoles 6–11 and benzobicyclo[3.2.1]-derivatives 23–
25 and 28–32 (Schemes 1 and 2, Figures 2 and 3) were 
previously synthesized and completely characteri-
zed.[14,15,19,20,22] They were prepared by photocylization or 
[2+2]-photocycloaddition reaction from the corresponding 
starting conjugated compounds in very good yields. The 
required styryloxazoles were synthesized in one step 
(Scheme 1) by Van Leusen reaction from aryl/heteroaryl 

































Scheme 1. General scheme for the synthesis of the investi-
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isocynide (TosMIC). The investigated hetero-naphthalene 
derivatives 26 and 27 are also obtained and isolated as 
photocyclization reaction side-products possessing the 
potentially interesting structure for biological activity. 
 In the case of 2/3-thienylethenyl- and 2/3/4-pyri-
dylethenyloxazoles synthesis the necessary unsatu-rated 
aldehydes were prepared by Wittig reaction from the 
corresponding aldehydes and formylmethylenetriphenyl-
phosphorane. 
 The investigated benzobycyclic photoproducts 23–
32 were prepared by photocycloaddition of starting 
conjugated substrates (photoproducts 23–25 and 28–32, 
Figure 3) or by photocyclization reaction (compounds 26 
and 27). 
Biology 
As it was mentioned before, 32 compounds were selected 
belonging to different types of heteropolycyclic photo-
products (Figures 2 and 3) and investigated their biological 
activity in proliferation and inflammation based assays 
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Figure 2. Structures of the investigated naphthoxazoles and 





























Figure 3. Structures of the investigated benzobycyclic photoproducts 23-32. 
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xazoles 2 and 5, and fused hetero-benzoxazoles 9 and 11 
inhibited TNFα protein expression in LPS stimulated PBMC 
(Figures 8 and 9), indicating possible antiinflammatory role 
which would be interesting to further investigate. On the 
contrary, these compounds did not show any effect on IL8 
(Figure 7) protein expression, another factor playing 
important role in inflammation. Concerning the exact 
structure of the tested compounds, naphthoxazoles 2 and 
5 possess the methoxy or methyl group in the structure at 
the specific positions of different aromatic rings, while 
hetero-benzoxazoles 9 and 11 have the condensed pyridine 
ring instead of the second aryl moiety. That is very 
important to clarify before the study of physico-chemical 
properties in general. 
 Both TNFα and IL8 are mainly produced by 
macrophages, they promote inflammation and act as 
neutrophil chemoattractants, while TNFα is also one of the 
most notable proinflammatory factors in cancer. 
Furthermore, related compounds 18, 19 and 20 with similar 
structure to compounds 2, 5, 9 and 11 were also tested in 
 
Figure 5. Effect of compounds 2, 5, 9 and 11 on proliferation of Jurkat cells after 72 h of incubation (n = 3). 
 
Figure 6. Effect of compounds 2, 5, 9 and 11 on proliferation of THP1 cells after 72 h of incubation (n = 3). 
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LPS stimulated PBMC assay where they achieved up to 40 
% of TNFα inhibition and again, no effect on IL8 expression 
(Supplementary figures 4 and 5) . The similarities in 
structure and activity of these compounds affirm the need 
to further address their antiinflammatory properties. It is 
evident that the position on the third (hetero) aromatic ring 
is very important for the antiinflammatory properties of the 
compounds (Scheme 3). Compounds 2, 18, 19 and 20 have 
different substituents on the same position of the con-
densed third aromatic ring, and on the same position 
compound 11 possesses the nitrogen atom. On this way the 
most important position for the substituents affecting the 
antiinflammatory activity is defined including the methoxy, 
dimethylamino, chloro substiturnts or the nitrogen atom as 
a part of the pyridine moiety (compounds 9 and 11) in the 
structure. Also, the methyl substituent on the middle 
aromatic ring (compound 5), or between the nitrogen and 
oxygen atoms in the oxazole ring (in combination with the 
methoxy substituent, compound 18) showed an important 
role for the investigated properties. 
 The effect of compounds on proliferation of several 
cancer cell lines (THP-1, Jurkat and HL-60) was also 
investigated. Tested concentrations of compounds did not 
exhibit any toxic or antiproliferative activity in these assays, 
during 72 h of incubation (Figures 4, 5 and 6). Some inhibi-
 
Figure 8. Effect of compounds 2, 5, 9 and 11 on TNFα production in LPS stimulated PBMC (n = 2). 
 
Figure 9. TNFα expression (pg/mL) in vehicle and LPS (1 
ng/mL) stimulated PBMC treated with reference compound 
dexamethasone and compounds 2, 5, 9 and 11 (n = 6 for 
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tion of proliferation up to 24 % was observed at the highest 
concentrations of compounds 9 and 11, however only in 
THP1 cells (Figure 6.). Overall, these findings further 
support that observed inhibition of TNFα expression is due 
to compounds activity, rather than the result of toxicity. 
Reference Compounds 
In the investigation of the biological activity of the tested 
compounds 1–32, staurosporine and corticosteroid 
dexamethasone were used as reference compounds 
(Figures 10 and 11). Their effects on proliferation of HL60 
(A), Jurkat (B) and THP1 (C) cells after 72 h of incubation 
(Figure 10) and on IL8 (A) and TNFα (B) production in LPS 
stimulated PBMC were presented and compared to the 
effects of the investigated photoproducts. Also, IC50 values 
determined for reference compounds in cell proliferation 
assay (staurosporine) and LPS stimulation assay (dexame-
thasone) are presented in Table 1. 
Physico-Chemical Properties 
As an initial attempt for better understanding and explan-
ing the biological activity of compounds 1–32, their physi-
co-chemical properties were also investigated. Experimen-
tal lipophilicity, as determined by RP-HPLC was expressed 
by using chrom logD. These values were in the range 1.89–
7.50 at pH 7.4. Physico-chemical properties of investigated 
 
Figure 10. Effect of reference compound staurosporine on proliferation of HL60 (A), Jurkat (B) and THP1 (C) cells after 72 h of 
incubation (n = 3). 
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compounds have been studied in terms of lipophilicity 
expressed as chrom logD values and calculated logP. 
 Experimental values show that the majority of the 
investigated compounds are lipophilic (Table 2), which can 
be favorable in CNS terapeutic area. Correlation between 
calculated logP and experimental Chrom logD values 
qualitative agreement was observed between calculated 
logP and experimental Chrom logD especially for fused 
hetero-benzoxazoles 9 and 11 (Table 2), compounds which 
also inhibited TNFα protein expression in LPS stimulated 
PBMC (Figure 8), indicating possible antiinflammatory role 
interesting to further investigate. In case of bicyclo[3.2.1]-
core correlation between calculated logP and experimental 
Chrom logD values did not show good precision in 
predicting lipophilicity, since Chrom logD is expected to 
account for the ionizability of investigated compounds. 
High-throughput chromatographic determination of lipo-
philicity enables quick classification of novel compounds. 
From the group of benzobicyclic compounds 23–32, there are 
no examples with promising antiinflammatory or antipro-
liferative activity. These physico-chemical properties and results 
for biological activity are the reason why these compo-unds are 
also tested for cholinesterase inhibitory activity and antioxidant 
characteristics, the benzobicyclo[3.2.1]-derivatives showed 
better results as potential cholinesterase inhibitors and the 
oxazole derivatives having better antioxidant properties.[43,44] 
 Even though calculated logD and logP values do not 
show great precision in predicting lipophilicity for analised 
compounds, it can be used for qualitative prioritization of 
virtual libraries (Figure 12). 
Table 1. IC50 values determined for reference compounds in cell proliferation assay (staurosporine) and LPS stimulation assay 
(dexamethasone). N/A = compound not tested. 
Compound IC50   (HL60) IC50 (Jurkat) IC50  (THP1) IC50 (IL8) IC50  (TNFα) 
staurosporine 6.4 nM 23 nM 47 nM N/A N/A 
dexamethasone N/A N/A N/A 80 nM 34 nM 
 
Table 2. Chrom logD values determined for some 
investigated compounds from the following equation: 
chrom logD = 0.0857 × CHI – 2. Chromatographic Hydro-
phobic Index (CHI) values have been determined from 
gradient retention times (tR) at pH 7.4. 
Compound CHIaverage Chrom logD LogP 
1 78.70 4.74 2.88 
2 81.34 4.97 2.65 
3 84.22 5.22 2.65 
4 88.05 5.55 2.97 
5 89.49 5.67 2.97 
6 64.55 3.53 2.05 
7 73.18 4.27 2.9 
8 74.14 4.35 2.9 
9 45.36 1.89 1.6 
11 45.60 1.91 1.57 
14 89.01 5.63 2.97 
22 79.42 4.81 2.88 
23 >100 >5 3.77 
24 71.26 4.11 2.58 
27 110.84 7.50 5.16 
28 n/a n/a 5.53 
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 Most CNS drugs have logP values less than 5 so it is 
easily absorbed in blood brain barrier where active 
diffusion of drug is likely to have most lipophilic area like 
lipid bilayer of membrane and if the value is less than 0 it 
will move toward hydrophilic compartment like blood 
serum. For fused hetero-benzoxazoles 9 and 11 it is 
achieved best correlation between Chrom logD and logP, 
but values are low for potential CNS drugs. Compound 29 
possessing the benzobicyclo[3.2.1]-octadiene structure has 
potential to cross BBB using active diffusion. 
 As the importance of physico-chemical properties of 
compounds at early stage of discovery of new drugs is now 
well established, according to the results in this study 
further investigatons will be performed on the amino 
derivatives of both groups of compounds. As it was 
concluded, the similarities in structure and activity of some 
representative compounds affirm the need to further 
address their antiinflammatory properties. The starting 
compound for the synthesis of the amino substituted 
naphthoxazoles at the defined position will be the chloro 
derivative 20, and the chloro derivative 28 for the group of 
benzobicyclo[3.2.1]-octadienes. The choliesterase inhibi-
tory activity of those new functional amines will be also 
investigated in the light of the obtained physico-shemical 
properties and concerning information about the biological 
targets and effects predicted by Pass (in silico). 
 
CONCLUSION 
Biological activity of naphthoxazoles 1–5 and 12–22, fused 
hetero-benzoxazoles 6–11 and benzobicyclo[3.2.1]-
derivatives 23–32 was investigated in proliferation and 
inflammation based assays. The tested compounds were 
prepared by photocylization or photocycloaddition 
reactions. Several naphthoxazoles and fused hetero-
benzoxazoles inhibited TNFα protein expression in LPS 
stimulated PBMC, indicating possible antiinflammatory role 
which would be interesting to further investigate. Physico-
chemical properties of tested compounds have been also 
studied using chromatographic lipophilicity measure, 
chrom logD and logP was calculated as the importance of 
physico-chemical properties of compounds at early stage of 
discovery of new drugs is well established. The similarities 
in structure and activity of some representative 
compounds affirm the need to further address their 
antiinflammatory properties. 
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